CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients.
about
Pharmacogenetic studies update in type 2 diabetes mellitusDrug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysisPharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group.The role of genetic factors and kidney and liver function in glycemic control in type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment.Identification of genetic variants in pharmacogenetic genes associated with type 2 diabetes in a Mexican-Mestizo populationNLRP3 Inflammasome Polymorphism and Macrovascular Complications in Type 2 Diabetes PatientsComputational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 DiabetesCYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patientsGenetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation.Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations.
P2860
Q26739350-7850B2D6-A95C-47D5-9FB0-27E067686BF5Q26784192-90A80F26-55EE-45C8-B4DE-A2E888F87CECQ30388214-395323BC-892C-4733-A878-A5D6035FF863Q33771570-A42CF7FC-E021-4156-A31F-BFBE0314BC0BQ33790423-A753403A-E92F-4168-8DA6-E0456D42DF9DQ33804241-4DEFD749-4479-4862-8A3E-FC80689698EFQ33858377-AE51F4B4-F16C-40FD-8BEB-5E3065741309Q35932364-61F2A98A-8F11-4A2F-BA78-0C3FCE827BCFQ37134345-BEBCFBCC-D723-40DD-91DD-0758D1DD092EQ37227417-277424AA-E188-450F-8173-C78FF2CBFB3BQ38711541-03D652C8-214E-4A3F-95E6-91DC32CA8925Q52322328-0D8D7BBC-0AF4-4E97-A26F-002BD341A296
P2860
CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
CYP2C9, KCNJ11 and ABCC8 polym ...... t in type 2 diabetes patients.
@en
CYP2C9, KCNJ11 and ABCC8 polym ...... t in type 2 diabetes patients.
@nl
type
label
CYP2C9, KCNJ11 and ABCC8 polym ...... t in type 2 diabetes patients.
@en
CYP2C9, KCNJ11 and ABCC8 polym ...... t in type 2 diabetes patients.
@nl
prefLabel
CYP2C9, KCNJ11 and ABCC8 polym ...... t in type 2 diabetes patients.
@en
CYP2C9, KCNJ11 and ABCC8 polym ...... t in type 2 diabetes patients.
@nl
P2093
P2860
P1476
CYP2C9, KCNJ11 and ABCC8 polym ...... t in type 2 diabetes patients.
@en
P2093
Andrej Janež
Jasna Klen
Vita Dolžan
P2860
P2888
P304
P356
10.1007/S00228-014-1641-X
P577
2014-01-18T00:00:00Z